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Abstract
Diabetic nephropathy is the leading cause of chronic renal disease and a major cause of
cardiovascular mortality. Diabetic nephropathy has been categorized into stages: microalbuminuria
and macroalbuminuria. The cut-off values of micro- and macroalbuminuria are arbitrary and their
values have been questioned. Subjects in the upper-normal range of albuminuria seem to be at high
risk of progression to micro- or macroalbuminuria and they also had a higher blood pressure than
normoalbuminuric subjects in the lower normoalbuminuria range. Diabetic nephropathy screening
is made by measuring albumin in spot urine. If abnormal, it should be confirmed in two out three
samples collected in a three to six-months interval. Additionally, it is recommended that glomerular
filtration rate be routinely estimated for appropriate screening of nephropathy, because some
patients present a decreased glomerular filtration rate when urine albumin values are in the normal
range. The two main risk factors for diabetic nephropathy are hyperglycemia and arterial
hypertension, but the genetic susceptibility in both type 1 and type 2 diabetes is of great
importance. Other risk factors are smoking, dyslipidemia, proteinuria, glomerular hyperfiltration
and dietary factors. Nephropathy is pathologically characterized in individuals with type 1 diabetes
by thickening of glomerular and tubular basal membranes, with progressive mesangial expansion
(diffuse or nodular) leading to progressive reduction of glomerular filtration surface. Concurrent
interstitial morphological alterations and hyalinization of afferent and efferent glomerular arterioles
also occur. Podocytes abnormalities also appear to be involved in the glomerulosclerosis process.
In patients with type 2 diabetes, renal lesions are heterogeneous and more complex than in
individuals with type 1 diabetes. Treatment of diabetic nephropathy is based on a multiple risk
factor approach, and the goal is retarding the development or progression of the disease and to
decrease the subject's increased risk of cardiovascular disease. Achieving the best metabolic
control, treating hypertension (<130/80 mmHg) and dyslipidemia (LDL cholesterol <100 mg/dl),
using drugs that block the renin-angiotensin-aldosterone system, are effective strategies for
preventing the development of microalbuminuria, delaying the progression to more advanced
stages of nephropathy and reducing cardiovascular mortality in patients with diabetes.
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Review
Diabetic nephropathy (DN) is the leading cause of
chronic renal disease in patients starting renal replace-
ment therapy [1] in the United States as well as in Brazil
[2]. It is associated with increased cardiovascular mortal-
ity [2,3]. DN has been classically defined as increased pro-
tein excretion in urine. Early stage is characterized by a
small increase in urinary albumin excretion (UAE), also
called microalbuminuria or incipient DN [4-7]. More
advanced disease is defined by the presence of macroalbu-
minuria or proteinuria. The latter is classically named
overt DN. In most cases, proteinuria and decreased
glomerular filtration rate (GFR) occur in parallel. Tradi-
tionally, GFR has been expected to decrease when pro-
teinuria is established, but not before. However, it is clear
today that some subjects could have DN without
increased UAE [8,9]. About 10% of subjects with type 2
diabetes mellitus (DM) will have low GFR without micro-
or macroalbuminuria [10]. This was also observed among
patients with type 1 DM and microalbuminuria [11].
The prevalence of DN varies according to ethnicity: it is
higher in African-Americans, Asians and Native-Ameri-
cans than in Caucasians [1,12]. African-Brazilians are
more susceptible to progress to end-stage renal disease
(ESRD) than people of European ancestry, but there
appears to be a similar prevalence of micro- or macroalbu-
minuria [13].
Among patients starting renal replacement therapy, the
incidence of DN continued to rise from 1991 to 2001 [1].
This observation could not be attributed to older age or
DM prevalence. From 1984-1996, the incidence of ESRD
treatment attributable to DM (ESRD-DM) per 100,000
diabetic population increased in all age groups. However,
in 1997-2002, ESRD-DM incidence decreased for people
younger than 65 years (by 28% for those younger than 45
years and by 19% for those aged 45-64 years), did not
change for those aged 65-74 years, and increased only
among persons aged 75 years or older (by 10% from
350.3 to 383.7) http://www.cdc.gov/mmwr/preview/
mmwrhtml/mm5443a2.htm. Although people younger
than 65 years had the highest incidence of ESRD-DM
prior to 1990, by 1999 their incidence was lower than in
the older ones http://www.cdc.gov/diabetes/statistics/
esrd/fig6.htm.
The increased incidence of ESRD attributable to DM sug-
gests that other factors are involved in the etiology of DN,
since a putative improvement in blood pressure (BP) lev-
els, increased use of angiotensin converting enzyme
(ACE) inhibitors and better glucose control due to lower
glycemic targets have been frequent in recent years.
Stages
According to UAE values, DN has been didactically cate-
gorized into stages. The cutoff values used [14] to charac-
terize these stages are described in Table 1.
Although microalbuminuria is considered a risk factor for
the development of macroalbuminuria, not all patients
progress to this stage, and some may regress to nor-
moalbuminuria [15,16]. The initial studies suggested that
about 80% of type 1 diabetic patients with microalbu-
minuria would progress to proteinuria over a period of 6
to 14 years [4-6]. More recent studies suggest that only 30
to 45% of microalbuminuric patients will progress to pro-
teinuria over 10 years of follow-up [15]. In fact, some of
them will present regression to normoalbuminuria. This
might be the result of more intensive glucose and BP con-
trol strategies employed in the last decade than in the ini-
tial studies. This regression of microalbuminuria is more
frequent among subjects with short duration of micro-
albuminuria, glicohemoglobin A1c (HbA1c) below 8%,
systolic BP <115 mm Hg, and favorable lipid profile
(serum total cholesterol <198 mg/dl and triglycerides
<145 mg/dl). Independent of the role as a prognostic fac-
tor for macroalbuminuria, the presence of microalbu-
minuria, reflecting a state of generalized endothelial
dysfunction, is a risk factor for cardiovascular disease and
mortality [17,18].
The cut-off values of urinary albumin to define the stages
of DN are arbitrary (Table 1). On the one hand, not all
Table 1: Diabetic nephropathy stages based on urinary albumin excretion
Stage Urine with marked time
(μg/min)*
24-hour urine
(mg/24 h)*
Random urine sample
Albumin concentration
(mg/l)**
Albumin/creatinine ratio
(mg/g)*
Normoalbuminuria < 20 < 30 < 17 < 30
Microalbuminuria 20 -- 199 30 -- 299 17 a 173 30 -- 299
Macroalbuminuria ≥ 200 ≥ 300 ≥ 174 ≥ 300
* Values according to the American Diabetes Association
** Gross et al., Diabetes Care 2005.Diabetology & Metabolic Syndrome 2009, 1:10 http://www.dmsjournal.com/content/1/1/10
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subjects will progress to overt DN, and some might even
regress as stated before. On the other hand subjects in the
upper-normal range of albuminuria seem to be at high
risk for complications. In patients with type 2 DM, the
progression to micro- or macroalbuminuria is more fre-
quent in individuals whose baseline UAE was normal but
above 2.5 mg/24 h [19]. Furthermore, in another study
after 10 years of follow-up, patients with type 2 DM and
UAE values above 10 μg/min were at 29 times higher risk
of developing DN [20]. Similar results were observed in
patients with type 1 DM [21]. Another interesting obser-
vation is that patients with type 2 DM and UAE in the
upper-normal range had higher BP than normoalbuminu-
ric patients in the lower UAE range [22]. This favors the
concept that UAE is a continuum similar to what has been
demonstrated for BP and cholesterol levels.
In the microalbuminuric stage, no decline in GFR is
expected. Once the subject has developed macroalbu-
minuria, the expected GFR decline is 1.2 ml/min/month
in type 1 DM [23]. This could be decreased by BP treat-
ment. In type 2 DM, the rate of GFR decline is less predict-
able. A mean decline of approximately 0.5 ml/min/
month [24] has been described, but in some patients GFR
may remain stable for long periods of time [25]. The
greater GFR decline is associated with more advanced dia-
betic glomerulopathy and worse metabolic control [26].
Screening and Diagnosis
The first step in screening for DN is to measure albumin
in an isolated urine sample [27]. The results of albuminu-
ria in an isolated sample can be expressed as albumin con-
centration (mg/l) or as albumin/creatinine ratio (mg/g)
[28]. Although albumin concentration may be influenced
by urine dilution/concentration, this measure appears to
be the best choice, considering its cost and accuracy [29].
Every abnormal albuminuria test should be confirmed in
two of three samples collected at a three to six-months
interval, due to the daily variability of UAE [30]. Screening
should not be performed under conditions that may
increase UAE, such as hematuria, acute systemic diseases
or fever, vigorous physical exercise, poor glycemic control,
uncontrolled arterial hypertension and decompensated
cardiac failure [31]. Bacteriuria had also been considered
a factor that could interfere in the measure of urinary
albumin [31-33]; but in a recent study this finding was
not confirmed, suggesting that it is not necessary to
exclude bacteriuria to measure albuminuria [34].
In situations in which UAE measurement is not available,
semiquantitative dipstick measurements of albuminuria
(for instance: Micral® Test II) can be used, although these
tests are less accurate [29].
The quantitative methods most commonly used to meas-
ure albuminuria are immunoturbidimetry, immunon-
ephelometry and radioimmunoassay. However, recently
it has been observed that an appreciable quantity of albu-
min is not detected by routine immunoassay methods,
defined as non-immunoreactive fraction, which results in
an underestimate of UAE [35-37]. On the other hand the
HPLC (high performance liquid chromatography) method
measures the immunoreactive and non-immunoreactive
fractions which compose the total intact albumin, allow-
ing the detection of earlier albumin elevations [37,38].
However, this method can overestimate UAE as observed
in some community studies, possibly due to the fact that
albumin peaks measured using this method can be con-
founded with other proteins [39]. Therefore, the signifi-
cance of total intact albumin, both to diagnose DN, and
for its association with cardiovascular disease has not yet
been well established.
DN screening must be performed when DM is diagnosed
in patients with type 2 DM, since these individuals may
have had a silent form of DM for some time already. For
patients with type 1 DM, it is recommended that screen-
ing be performed beginning in the fifth year after DM
diagnosis or earlier if the DM is chronically poorly com-
pensated, or if the patient is an adolescent. In all cases, if
albuminuria is normal, screening must be repeated annu-
ally [27].
Although the measurement of albuminuria is essential to
diagnose DN, there are some patients who present
decreased GFR when UAE values are normal. Based on
this, the classification of the National Kidney Foundation
can also be used to stage chronic kidney disease in these
patients (Table 2) [27]. It is recommended that GFR be
routinely estimated for appropriate screening of DN. GFR
can be measured using specific techniques such as inulin
clearance, 51Cr-EDTA, 125I-iothalamate, and iohexol.
However, in clinical practice, GFR is estimated by equa-
tions that take into account serum creatinine concentra-
tion and some or all of the following variables: age, sex,
body weight and race. The equation recommended by the
National Kidney Foundation is that of the study on Modifi-
cation of Diet in Renal Disease (MDRD): GFR (ml/min/
l.73 m2) = 186 × [serum creatinine (mg/dl) -1,154 × age
(years) -0,203 × (0.742 if a woman) × (1.21 if African-Amer-
ican)]. If the creatinine measurement method is cali-
brated, the formula should use factor "175" in place of the
value "186". The Cockroft-Gault formula, creatinine
depuration (ml/min) = [140 - age (years)] × weight (kg)/
[72 × serum creatinine (mg/dl)] × 0.85 (if a woman) is
less precise [40]. The reference values of GFR for young
individuals are 90 to 130 ml/min/l.73 m2, with the reduc-
tion of these values as age increases, in the order of 10 ml/
min/decade after the age of 50 years [41].Diabetology & Metabolic Syndrome 2009, 1:10 http://www.dmsjournal.com/content/1/1/10
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Serum creatinine concentration should not be used as an
isolated index for the evaluation of renal function, since
its measure is affected by other factors besides GFR itself,
such as tubular secretion, extrarenal generation and pro-
tein ingestion.
Special Situations
Patients with micro- or macroalbuminuria, after the con-
firmation of diagnosis (2 measurements), should undergo
a complete evaluation concerning differential diagnosis
and assessment of renal function. DN is associated with
several other conditions that need to be addressed making
the management of these patients very complex. However
this is not within the scope of the present manuscript and
a detailed approach could be found in a recent review
[30].
Diabetic patients can have other kidney diseases. The dif-
ferential diagnosis is usually based on the history, physi-
cal examination, laboratory evaluation and kidney
imaging. Renal biopsy has only been recommended in
special situations. In the presence of micro or microalbu-
minuria and diabetic retinopathy in a patient with long
term DM (e.g. >10 years) the assumption that DM is caus-
ing the renal disease is generally correct. Conversely, in
diabetic patients with type 2 DM with a fast increment in
albuminuria and in patients with type 1 DM where mac-
roalbuminuria develop in the absence of diabetic retinop-
athy a differential diagnosis should be carried out.
However, in type 2 diabetic patients the time of DM onset
is usually unknown and retinopathy could be absent in a
significant proportion (28%) of patients with albuminu-
ria [42]. In summary, absent retinopathy, short duration
of DM and faster decline in GFR and/or albuminuria
increment are indications to suspect of nondiabetic renal
disease [43]. If after a non-invasive evaluation the diagno-
sis is still unclear, a kidney biopsy should be discussed. In
type 2 DM the prevalence of nondiabetic renal disease
could vary from 12 to 38% [42,44,45]. All the kidney
biopsy data are derived from retrospective studies. The dif-
ferences in the prevalence of non-diabetic lesion observed
in the studies probably reflect different criteria used to
indicate renal biopsies. In one study, subjects with type 2
DM, gross proteinuria (>1 g) without retinopathy, and
hematuria and no retinopathy, 19% of patients with con-
firmed DN had another glomerulopathy associated [45].
In this study, patients without diabetic glomerulosclerosis
had a better prognosis than those with diabetic glomeru-
losclerosis [45]. Another aspect that needs to be addressed
is that it is not clear if there is additional benefit of detect-
ing other nephropathies in the management of these
patients.
Risk Factors
The two main risk factors for DN are hyperglycemia and
arterial hypertension. However, DN develops in only
about 40% of patients, even in the presence of hyperglyc-
emia and elevated BP for long periods of time. This obser-
vation raised the concept that DN will develop only in a
susceptible subset of patients [46-48]. Furthermore, fam-
ily studies have confirmed a genetic contribution for the
development of DN in both type 1 and type 2 DM [49-
53]. Once DN is present, progression factors may act,
favoring evolution to more advanced stages. There is evi-
dence that some factors involved in the development of
proteinuria are also common to the loss of GFR, but oth-
ers are unique to each one of them [54].
Hyperglycemia
Hyperglycemia is a significant risk factor for the develop-
ment of microalbuminuria, both in type 1 and in type 2
DM [21,55,56]. A reduction of 1% in HbA1c is associated
with a 37% decrease in microvascular endpoints [57]. In
the presence of micro- and macroalbuminuria the role of
metabolic control is less defined, even though some stud-
ies showed a deleterious effect of high glucose levels on
GFR [58,59]. Moreover, it was demonstrated that pancreas
transplantation reversed renal damage in type 1 DM
patients with mild to advanced DN lesions [60]. Recently
a large trial also reinforced the importance of intensive
treatment of DM to decrease the microvascular complica-
tions [61].
Arterial Hypertension
Arterial hypertension is a main risk factor for the develop-
ment of DN [56,62], and probably the best known rele-
vant factor related to its progression. Analysis of UKPDS
showed that every 10 mmHg reduction in systolic BP is
Table 2: Chronic kidney disease stages
Stage Description GFR (ml/min/1.73 m2)
1 Renal damage* with GFR N or ↑≥ 90
2 Renal damage* with GFR slightly ↓ 60-89
3 GFR moderately ↓ 30-59
4 GFR severely ↓ 15-29
5 End stage chronic renal failure <15 or dialysis
*Renal damage is defined by abnormalities in the urine and blood tests, imaging exams or in pathology
GFR = glomerular filtration rateDiabetology & Metabolic Syndrome 2009, 1:10 http://www.dmsjournal.com/content/1/1/10
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associated with a 13% reduction in the risk of microvascu-
lar complications, with the smallest risk among those
patients with systolic BP <120 mm Hg [63].
Smoking
Smoking is a risk factor for DN [19,56] and might contrib-
ute to its progression [64]. Although some studies did not
confirm these observations [55,59,65], it is strongly rec-
ommended to quit smoking in any phase of DN, also aim-
ing to reduce the associated cardiovascular and cancer
risk.
Dyslipidemia
In type 2 DM, elevated serum cholesterol is a risk factor for
the development of DN [55,56]. In type 1 DM patients
increased serum triglycerides, total and LDL-cholesterol
were associated with micro- and macroalbuminuria
[66,67]. High serum cholesterol also seems to be a risk
factor for GFR loss in macroalbuminuric type 1 diabetic
subjects [68].
Proteinuria
Proteinuria itself could lead to progression of DN. Pro-
teinuria >2 g/24 h is associated with a greater risk of ESRD
[69]. Increased leakage of albumin may induce glomeru-
lar damage probably through activation of inflammatory
cascades [70]. This would be a reason to target decreased
urinary albumin excretion in DN treatment.
Glomerular hyperfiltration
Elevated GFR values are present in about one third of type
2 DM patients [71,72] and theoretically it could cause DN
due to glomerular damage [73]. Studies led to controver-
sial findings regarding its role as a risk factor for the devel-
opment of DN [20,71,74]. Type 2 DM patients with a
single-kidney more often present increased UAE levels
[75,76]. On the other hand, type 1 DM patients with only
one kidney do not have a more aggressive disease [77].
Glomerular hyperfiltration probably plays a small role, if
any, in the development of DN [78].
Dietary factors
Increased dietary protein intake seems to be associated
with the presence of higher UAE values, at least in patients
with type 1 DM [79]. In patients with type 2 DM this asso-
ciation has not been documented. The source of proteins
in the diet also seems to be related to the presence of DN.
A higher intake of fish protein is related to a lower risk of
microalbuminuria in type 1 DM patients [80]. The mech-
anisms involved in these findings are unknown but prob-
ably related to hemodynamic factors [81].
Regarding the dietary lipid content, an association has
been observed between the higher intake of saturated fat
and the presence of microalbuminuria in patients with
type 1 DM [82]. In patients with type 2 DM, very recently,
it was observed that the presence of microalbuminuria
was associated with the lower content of polyunsaturated
fatty acids, especially those of vegetal origin [83]. In a
study performed with patients with type 1 and type 2 DM,
followed for 6 years, it was also demonstrated that those
who evolved with regression of the DN presented a higher
intake of polyunsaturated fatty acids and a lower intake of
saturated fatty acids [84].
Genetic risk factors
The exact genetic model underlying DN susceptibility is
uncertain, but theoretically few genes with a major contri-
bution and some with minor interaction with the envi-
ronment could cause DN [47,48]. Unfortunately, no gene
with a major effect had been identified so far. The knowl-
edge of which gene(s) predisposes to DN will allow the
identification of patients at high risk for this complica-
tion, and adoption of preventive measures.
In genetic studies the clear definition of the phenotype,
DN, is very important. DN could be defined by different
parameters: for instance, the presence of microalbuminu-
ria, macroalbuminuria, ESRD or decreased GFR. Some
genes probably are involved in the development of pro-
teinuria, others with decline in GFR and some will be
involved in both situations [47,48]. Therefore, a more
comprehensive definition of DN used in the genetic stud-
ies is important to make the results more comparable.
A familial aggregation of DN has been demonstrated in
studies of sibling-pairs [49,53,85], parent-offspring pairs
or studies of extended families [51,52]. One practical
application of the studies with diabetic siblings is that the
chance of having DN increases 2-3 times if the subject's
sibling has DN when compared to the subject who has a
normoalbuminuric sibling, either in type 1 or type 2 dia-
betes [49,53].
Recent advances in technology make easier to look for
regions in whole genome linked to different DN pheno-
types [86-88]. This approach identified regions and puta-
tive genes not previously known to be associated with DN
and it could raise new candidate genes. Moreover, new tar-
gets for drug development may come into sight, since
some of the genes found are novel and have not been pre-
viously implicated in the pathogenesis of DN.
Association studies of candidate genes have been per-
formed aiming to identify polymorphic variants associ-
ated with DN or with different degrees of renal disease.
Often, genes that play a role in the expression of proteins
that are related to the modulation of cytokines, proteins
involved in the glycid and lipid metabolism, in the forma-
tion of extracellular matrix, in blood pressure homeosta-Diabetology & Metabolic Syndrome 2009, 1:10 http://www.dmsjournal.com/content/1/1/10
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sis, and in insulin sensitivity, have been considered
candidates for the development of DN [9,30,89]. How-
ever, the studies have not been successful in identifying
genes that consistently show an association with DN. Rep-
lication studies have demonstrated conflicting results
[90]. The evaluation of 360 thousand polymorphisms in
patients with type 1 DM, with and without DN, showed a
total of 13 polymorphisms located at 4 loci in two inde-
pendent cohorts of subjects strongly associated with the
presence of DN [87]. Some of these polymorphisms are
located in genes highly expressed in the kidney with DN,
and its development over time [87].
Another approach that has been used to investigate the
genetics of DN involves the study of microRNAs role on
this process. These are non-encoding short RNAs that
induce post-transcriptional protein modifications. Little is
known about these molecules and their role in DN. In a
study, microRNA mirR-192 expression was increased in
the glomeruli of rodents with DM [91]. Their induction by
TGF-β in mesangial cells caused increased collagen syn-
thesis and suggests that this type of molecule may be
implicated in the development of DN, opening up a new
prospect of research in elucidating the pathogenesis of
this DM complication. The replication of this finding and
this type of approach must be better explored in studied
conducted in human beings.
As previously stated, Brazilians of African descent have
more aggressive renal disease than people of European
ancestry [13]. This could be due to several reasons, such as
the presence of different risk factors, different access to
medical attention, and socioeconomic differences. How-
ever, none of the assessed known risk factors were differ-
ent between African and Europeans [13,92] make unclear
an explanation for the different rates of DN between black
and white subjects. Unfortunately, data on socioeco-
nomic status were unavailable. An alternative explanation
for this observation, but hard to prove, would be a differ-
ent genetic susceptibility.
Pathology
DN in individuals with type 1 DM is initially character-
ized by a thickening of the glomerular and tubular basal
membrane, with progressive mesangial expansion leading
to the progressive reduction of the glomerular filtration
surface [93]. Concurrent interstitial morphological altera-
tions also occur, as well as hyalinization of the afferent
and efferent glomerular arterioles [93]. Mesangial expan-
sion can be diffuse (diabetic glomerulosclerosis) or with
areas of marked mesangial expansion, forming roundish
and fibrillar zones, with nuclei in palisade (nodular
glomerulosclerosis, Kimmelstiel-Wilson nodes). While
mesangial expansion is the critical lesion which leads to
progression to loss of renal function, damage to the tubu-
lar glomerular junction, to the tubules and to the inter-
stice determines progression to ESRD [87,91].
Podocytes damage also appears to be involved in the
glomerulosclerosis process. In a study conducted in Pima
Indians, highly susceptible to developing DN, a smaller
number of podocytes per glomerulus was the greatest pre-
dictor of increased UAE and progression to clinical DN
[93]. When this finding was present, normoalbuminuric
individuals had a higher risk of progressing to renal dis-
ease than those who did not have a podocyte lesion [93].
In addition, nephrine, a protein synthesized by the podo-
cyte and considered vital to the stability of the glomerular
barrier, has its expression reduced in DN [94]. The admin-
istration of ACE inhibitors results in the expression of
nephrine at levels similar to those of individuals with DM
without DN [95].
In a subgroup of patients with DM, loss of renal function
precedes the development of microalbuminuria. This
group presents more advanced glomerular lesions than
those that present microalbuminuria [93].
Renal lesions in individuals with type 2 DM are more
complex than in individuals with type 1 DM. The preva-
lence of a renal lesion that is non-typical for DM in indi-
viduals with type 2 DM is high, reaching 10 - 30% of
subjects with proteinuria [91,93]. In a minority, the his-
topathological aspects are similar to the typical lesion of
subjects with type 1 DM. The rest presents only mild or
absent DN, with or without tubulointerstitial alterations,
arteriolar alterations or diffuse glomerulosclerosis [93].
The tubulopathy is possibly related to persistent hypergly-
cemia and changes related to age, atherosclerosis and arte-
rial hypertension [91]. Despite the heterogeneity of the
lesions and the impact of diseases such as arterial hyper-
tension on individuals with type 2 DM, in a large cohort
of individuals with type 2 DM, the severity of the lesions
was correlated with the progression of DN and the veloc-
ity of GFR loss [26].
Pathophysiological Mechanisms
Hemodynamic factors
In an initial phase, DN is characterized by glomerular
hyperfiltration due to a reduction in the resistance of the
afferent and efferent glomerular arterioles, and conse-
quent increased renal perfusion. Although the mecha-
nisms that lead to glomerular hyperfiltration are unclear,
obesity and the release of a number of proinflammatory
factors and growth factors that occur in DM appear to
have a role [96,97]. In a study performed by our group,
the levels of endothelin 1 (ET-1), an important vasocon-
strictor, were correlated with UAE, and its plasma levels
were progressively higher according to the higher degree
of DN [98]. This early defect in autoregulation of renalDiabetology & Metabolic Syndrome 2009, 1:10 http://www.dmsjournal.com/content/1/1/10
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perfusion makes it easier for albumin to leak from capil-
laries to renal glomerulus, and leads to compensatory
increase of mesangial matrix, thickening of the glomerular
basement membrane and podocyte damage. Albuminuria
also activates a series of inflammatory pathways through
tubular cells and feeds this process [91]. In addition, the
mechanical stress resulting from renal hyperperfusion
induces the release of cytokines (TNF-α), growth factors
(VEGF, TGF-β1), cholesterol and local triglycerides that
induce the accumulation of proteins from extracellular
matrix, leading to mesangial expansion and glomerulo-
sclerosis. A reduction of TGF-β1 by blocking the renin-
angiotensin-aldosterone system retards the progression of
DN and preserves glomerular morphology [99].
Hyperglycemia and advanced products of non-enzymatic 
glycosilation
Persistent hyperglycemia is a strong risk factor for DN and
causes the proliferation of mesangial cells and their
matrix, as well as the thickening of the basement mem-
brane. Hyperglycemia increases the expression of vascular
endothelial growth factor (VEGF) in podocytes causing
increased vascular permeability. Hyperglycemia also
increases the generation of advanced products of non-
enzymatic glycosilation of proteins through activation of
aldol reductase pathway and protein kinase C (PKC). The
final products of non-enzymatic glycosilation are bound
to collagen and proteins that constitute the glomerular
basement membrane and make the glomerular barrier
more permeable to the passage of proteins, resulting in
increased UAE [94,100-104].
Cytokines
A series of circulating markers of inflammation such as C
reactive protein and interleukin 1, 6 and 18, and tumor
necrosis factor are increased in DN and their levels corre-
late with albuminuria and progression to ESRD. In addi-
tion, hyperglycemia, TGF-β1 and angiotensin II stimulate
the secretion of VEGF, causing the production of endothe-
lial nitric oxide, vasodilation and glomerular hyperfiltra-
tion [94]. Hyperglycemia, possibly mediated by oxidative
stress, also induces angiotensin II to the synthesis of TGF-
β, type IV collagen and fibronectin, contributing to pro-
gressive glomeruloesclerosis [87].
Inflammatory factors are also involved in the develop-
ment of tubulointerstitial lesion, and appear to lead to
accumulation of macrophages in the tubular interstice in
animal models designed to study DN. Macrophages also
produce free radicals, inflammatory cytokines and pro-
teases that induce tubular damage [91]. Furthermore,
glomerular and renal cells also produce a series of inflam-
matory factors when they are exposed to glomerular
hyperfiltration and increased UAE, intensifying this proc-
ess [91].
Treatment
The principles of prevention and treatment of DN are the
same. However, the role of each factor could be different
in each stage of disease. It is important to define the DN
stage that is the target of intervention (microalbuminuria,
proteinuria or GFR) and the outcome of interest. Two
recent meta-analyses have demonstrated different results
when evaluating different outcomes, such as proteinuria,
GFR decline or progression to ESRD [105,106]. Both, ACE
inhibitors and angiotensin receptor blockers (ARBs) seem
to be effective reducing proteinuria and decreasing the cre-
atinine doubling rate, but not decreasing mortality [106].
Probably the best treatment is a multiple risk factor inter-
ventional approach, but due to a practical point of view
each aspect will be addressed individually. The goal to be
pursued is retarding the development or progression of
DN and to decrease the subject's cardiovascular risk and
mortality.
In normo- or microalbuminuric subjects, the aim of treat-
ment is to intervene at arterial hypertension, hyperglyc-
emia, smoking habit and probably dyslipidemia. Even in
the absence of clear data showing that the management of
these risk factors individually is beneficial to DN, they are
also risk factors for cardiovascular disease and should be
aggressively treated [30].
Clinical trials have demonstrated that intensive treatment
of hyperglycemia is associated with a decreased risk for
the development of DN in type 1 and type 2 diabetic
patients [107-110]. In type 1 and type 2 subjects the effect
of intensive therapy could be seen many years later
[108,111]. The effect of the intervention in hyperglycemia
in type 1 macroalbuminuric subjects is not so clear
[107,112,113]. This became more evident in the EDIC/
DCCT follow up study [108]. In the Kumamoto study,
prevention of macroalbuminuria was observed in type 2
DM patients intensively treated [110].
Recent studies designed to evaluate the benefit of inten-
sive glycemic control in large sets of patients showed a
minor protective effect on the development of progres-
sion of albuminuria [61,114]. In the Intensive Blood Glu-
cose Control and Vascular Outcomes in Patients with
Type 2 Diabetes (ADVANCE) trial, the group in the inten-
sive arm for an average of 5 years showed a small reduc-
tion in the number of cases with new-onset
microalbuminuria compared to the standard therapy
group (23.7 vs. 25.7%) [61]. No effect was observed in the
serum creatinine values [61]. The same was observed in
the Glucose Control and Vascular Complications in Veter-
ans with Type 2 Diabetes (VADT) study [114]. Patients in
the intensive arm for a mean of 5.6 years did not show any
benefit regarding changing serum creatinine or GFR val-Diabetology & Metabolic Syndrome 2009, 1:10 http://www.dmsjournal.com/content/1/1/10
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ues [114] and a minor effect on albuminuria levels was
observed [114].
Treatment of hypertension leads to an important risk
reduction in cardiovascular and microvascular events. In
the UKPDS, a reduction from 154 to 144 mm Hg on systo-
lic BP reduced the risk for the development of microalbu-
minuria by 29% [115]. BP targets for patients with DM are
lower (130/80 mm Hg) than those for patients without
DM [116]. In the Hypertension Optimal Treatment
(HOT) study a reduction of diastolic BP from 85 to 81
mm Hg resulted in 50% reduction in the risk of cardiovas-
cular events in diabetic but not in non-diabetic patients
[117]. In the presence of microalbuminuria the treatment
of hypertension, irrespective of the agent used, produced
a beneficial effect on albuminuria [118].
Aggressive treatment of hypertension should be estab-
lished in subjects with DM. A discussion of agents used to
treat hypertension in patients with DN are beyond the
scope of this manuscript, and recent guidelines [108,116]
and excellent reviews in this subject are available
[30,119,120].
In order to reach the BP goal of 130/80 mmHg in diabetic
patients in general [116] or 125/75 mmHg in patients
with proteinuria >1.0 g/24 h and increased serum creati-
nine, three to four antihypertensive agents are usually nec-
essary [121].
The choice of anti-hypertensive agents to use is in some
way not a problem in clinical practice, because to reach
the BP goals the majority of patients will need several
agents. However, due to the known renoprotective effect
of ACE inhibitors and ARB, these agents (see below)
should be used initially associated with a diuretic.
Renin-Angiotensin System (RAS) Blockade
ACE inhibitors could be used in normotensive subjects to
prevent or postpone the development of microalbuminu-
ria [122]. The aim of ACE inhibitors and ARBs use is not
only to diminish the risk for the development of micro-
and macroalbuminuria [123-125] but also to decrease the
occurrence of cardiovascular events [124]. However, a
recent 5 year multicenter randomized controlled trial
involving 285 normoalbuminuric, normotensive patients
with type 1 DM failed to show any improvement in
biopsy parameters with losartan (100 mg daily) or enal-
april (20 mg daily) compared to placebo [126]. Surpris-
ingly, the 5-year cumulative incidence of
microalbuminuria was 17% with losartan, significantly
greater than with placebo (6%, P = 0.01). The enalapril
group had a similar incidence of microalbuminuria (4%,
P = 0.96) in comparison to the placebo group [126].
RAS blockade with ACE inhibitors or ARB confers an addi-
tional benefit on renal function. This renoprotective effect
is independent of BP reduction [118,127]. These drugs
decrease UAE and the rate of progression from microalbu-
minuria to more advanced stages of DN. A meta-analysis
of 12 trials in non-hypertensive microalbuminuric type 1
diabetic patients showed that ACE inhibitors decreased
the risk of progression to macroalbuminuria by 60%, and
increased the chances of regression to normoalbuminuria
[128]. Therefore, the use of ACE inhibitors or ARB is rec-
ommended for all microalbuminuric patients, even if nor-
motensive [14]. ARBs were also effective in reducing the
development of macroalbuminuria in microalbuminuric
type 2 diabetic patients [127,129].
The aggressive treatment of hypertension has a strong
beneficial effect in reducing GFR decline in proteinuric
type 1 diabetic patients [130]. This reduction in GFR
decline was predicted by reduction in albuminuria [131].
According to the MDRD trial, the lower the BP the greater
the preservation of renal function in non-diabetic patients
[132]. Patients with proteinuria >1 g/day and renal insuf-
ficiency had a slower decline in renal function when BP
was <125/75 mm Hg [132]. Addition of ACE inhibitors in
proteinuric type 1 [133] or ARB in macroalbuminuric type
2 [134,135] diabetic patients has a beneficial effect in
decreasing proteinuria and reducing renal function
decline. The effect of ARBs on protein excretion could be
noted within 7 days after starting the treatment, and may
persist after [136]. It seems to be independent of BP reduc-
tion [127] and has a dose response effect beyond the
doses needed to control BP [137]. An acute increase in
serum creatinine up to 30 to 35% that stabilizes within 2
months might occur and it is not a reason to stop the treat-
ment [138]. Increase in serum creatinine above these val-
ues should raise the possibility of renal-artery stenosis
[138,139]. Another limitation to the use of ACE inhibitors
is hyperkalemia, especially among those with renal insuf-
ficiency [138]. Acute hyperkalemia (>5.5 mEqL) is an
indication to stop these medications. Therefore, albu-
minuria, serum creatinine and potassium should be
checked monthly in the first 2 to 3 months after starting
treatment with ACE inhibitors or ARB [138,139].
ACE inhibitors and ARB interrupt the RAS at different lev-
els, and the combination of these classes of drugs (RAS
dual blockade) has been proposed [140] as an alternative
to treat DN. It has been suggested that this association
would have an additive effect on renoprotection. The
combination of ARB and ACE inhibitors are effective in
reducing UAE ratio in hypertensive patients with type 2
DM when compared to each drug alone. However, this is
also associated with lower BP values in the group that
used both drugs [140,141]. A recent large trial (ONTAR-
GET) in diabetic and nondiabetic subjects showed thatDiabetology & Metabolic Syndrome 2009, 1:10 http://www.dmsjournal.com/content/1/1/10
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the association of the two classes of drugs had a major
effect on decreasing proteinuria but not on GFR decline or
mortality [142]. In fact, a worse effect on GFR and mortal-
ity was observed. Analyzing the subgroups, the increased
mortality came from the less sick subjects. Among diabetic
subjects no increased mortality was observed, but also no
benefit from the dual blockage was observed [142]. The
VA NEPRHON-D study aimed to evaluate this issue is
patients with type 2 DM [143].
Another step that has been proposed to be blocked is the
aldosterone action. Adding the aldosterone antagonist -
spironolactone - to ARBs [144] or ACE inhibitor [145] is
also more effective in reducing UAE and BP in type 2 dia-
betic patients than each drug alone. A recent meta-analy-
ses that included diabetic and non-diabetic subjects
demonstrated that the addition of aldosterone antago-
nists in patients already on ACE inhibitors and ARBs
reduces proteinuria in chronic kidney disease [146]. This
was not associated with an improvement on GFR, but
increases the risk of hyperkalemia. Long-term effects of
these agents on renal outcomes, mortality, and safety
need to be determined [146].
More recently, the dual blockage of the renin-angiotensin-
aldosterone system with aliskiren, a direct renin inhibitor,
and losartan at maximal recommended dose (100 mg
daily) showed a greater reduction in proteinuria (20%)
compared to losartan and placebo [147]. The effect does
not seem to be due to anti-hypertensive effect. However,
this was a short duration study (12 weeks) and long term
studies are needed. The ongoing trial ALTITUDE might
answer some of these questions [148]. This placebo con-
trolled, randomized trial intends to follow-up about 8600
subjects during two years and compare the effect of
aliskiren added to standard treatment (ACE or ARBs)
[148]. The results will be available by 2012.
Hyperglycemia treatment peculiarities
The treatment of DM is not the aim of the present review,
but a few special remarks could be made regarding the
treatment of hyperglycemia in a patient with renal disease
(Table 3).
Metformin is the standard therapy for patients with type 2
DM and will only be briefly discussed here. Metformin is
contraindicated when serum creatinine is above 1.5 mg/dl
in men and 1.4 mg/dl in women due to the increased risk
of lactic acidosis [149]. However, these values are being
questioned [150]. In these creatinine ranges, some sub-
jects will be using metformin on chronic renal disease
stages II and III [151].
Sulfonylureas and their metabolites, except glimepiride,
are eliminated via renal excretion and should be used with
caution in patients with GFR [152]. Glibenclamide is a
potent drug and has been known for a long time. It is low
cost and available in the public health system. However,
it presents a high risk of hypoglycemia. It has active
metabolites that increase in patients with decreased GFR,
and its pharmacological action is such that the use of glib-
enclamide is not recommended from stage 3 onwards
[153,154]. Among the sulfonylureas there is also glipizide
which carries a lower risk of hypoglycemia being and
alternative on this situation [154]. Glipizide can be used
in chronic renal disease stages 3 and 4. It could still be
used in stage 5, with a therapeutic adjustment. Glimepir-
ide is a third generation sulfonylurea with a slightly higher
cost and a lower risk of hypoglycemia. However, it is
believed that it has a few active metabolites filtered by the
kidneys what could be potentially related to higher risk of
hypoglycemia compared to glipizide.
Repaglinide [155] and nateglinide [156] have a short
duration of action, are excreted independently of renal
function and have a safety profile in patients with renal
impairment. These drugs, like the sulfonylureas, are insu-
lin secretagogues, but they act in different cellular mem-
brane channels, and this brings some pharmacological
properties such as quick initial action, non-prolonged
action and greater effect on post-prandial glycemia. A flex-
ible aspect of this drugs making therapeutic management
easier is the lower risk of hypoglycemia because of the dif-
ferent connection of the membrane channels. But one
side effect described similar to observed with the sulfony-
lureas is weight gain. Its cost is higher than that of sulfo-
nylureas, but theoretically it has a less deleterious effect
on beta cells. Among the glinides, the first choice would
be repaglinide because of the low risk of hypoglycemia,
and it can be used in stage 3 and stage 4 [155,157]. Data
in the literature are not sufficient to indicate the use of this
drug in chronic renal disease stage 5. Nateglinide would
be at a disadvantage because it is less potent, and it has
active metabolites that can increase the risk of hypoglyc-
emia in subjects with decreased GFR [158,159].
Acarbose is a drug that is not potent to reduce HbA1c.
However, as its pharmacological action principle is the
inhibition of enzyme alpha glycosidase in the small
bowel, reducing glucose absorption in the gastrointestinal
tract, it is a useful drug to adjust post-prandial hyperglyc-
emia. The metabolism of this drug is practically 100% gas-
trointestinal, part is excreted in the urine and most of it in
the feces, and a small form is excreted in the form of the
active metabolite [153,160]. The concern of using acar-
bose in subjects with chronic kidney disease is the accu-
mulation of these metabolites that may lead to hepatic
lesions. Thus, acarbose would be contraindicated in sub-
jects with chronic renal disease. There are insufficient data
in the literature to use this drug with a creatinine greaterDiabetology & Metabolic Syndrome 2009, 1:10 http://www.dmsjournal.com/content/1/1/10
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Table 3: Treatment of hyperglycemia in the patient with type 2 diabetes mellitus and chronic kidney disease
Stage of Renal Disease
Clearance Reduction of 
HbA1c
Risk of 
hypoglycemia
III IV V
Glibenclamide 
[153,154]
Hepatic metabolism: 
100%.
Excretion: bile and 
feces 50% and urine 
50%
-1.5% High 
(active metabolites)
Avoid Avoid Avoid
Glipizide [154] Excretion: 
metabolites 90% in 
urine and feces. 10% 
excreted without 
metabolization
-1.5% Low Can be used Can be used Can be used 
(adjustments)
Glimepyride Hepatic metabolism 
100%.
Excretion: urine 
60% and feces 40%
-1.5% Low Can be used Can be used Use with care
Repaglinide 
[155,157]
Hepatic metabolism: 
100%.
Excretion: 10% 
urine and 90% feces
-1.0% Low Can be used Can be used Use with care.
Adjust dose
Nateglinide 
[156,158,159]
Hepatic metabolism: 
85%.
Excretion: urine 
83% and feces 10%. 
15% excreted 
inactive in urine
-0.7% High 
(active metabolites)
Use with care Use with care Avoid if possible
Acarbose* 
[153,160]
Excretion: urine 
34%, feces 51% and 
<2% in urine in the 
free or active 
metabolic form
-0.6% Low Can be used Can be used Avoid
Rosiglitazone [162] Hepatic metabolism 
and excretion in the 
urine, of rather 
inactive metabolites 
in the urine 64% and 
feces 23%
-0.6 to 1.5% Low Can be used Can be used Can be used
Pioglitazone [162] Hepatic metabolism 
and excretion in 
urine of rather 
inactive metabolites 
in the urine 15% and 
feces 85%
-0.6 to 1.5% Low Can be used Can be used Can be used
Sitaglipitine 
[171,172]
Excretion: urine 
87% and feces 13%, 
in an unaltered 
form.
-0.7% Low Can be used Can be used.
Reduce dose 50%
Can be used.
Reduce dose 75%
Vildagliptine Excretion: urine: 
85% and feces 15%.
-0.7% Low Can be used Can be used Not recommended
Exanetide [173] Metabolism and 
renal excretion
-1.0%** Low Can be used Not recommended Not recommendedDiabetology & Metabolic Syndrome 2009, 1:10 http://www.dmsjournal.com/content/1/1/10
Page 11 of 17
(page number not for citation purposes)
than 2 mg/dl. It could be considered up to stage 3, and it
should be avoided in stages 4 and 5 [153,160].
Glitazones, represented by rosiglitazone and pioglita-
zone, act through the PPR gamma system and are insulin
sensitizer drugs that increase the muscle uptake of glucose
and diminish the atherogenic profile of the DM patient,
and could be used in renal failure [161,162]. Rosiglita-
zone has been shown to decrease UAE in type 2 diabetic
patients as compared to glyburide, suggesting a beneficial
effect in the prevention of renal complications of type 2
DM [163]. This antiproteinuric effect occurs also in
nondiabetic disease [161,164,165]. The side effects
include anemia, water retention, weight gain and poten-
tial hepatotoxicity due to the accumulation of its metabo-
lites. Recently, cardiovascular safety and the risk of
increased incidence of fractures have been discussed
[166,167]. Both would present a low risk of hypoglycemia
and could theoretically be used in the different stages of
chronic renal disease without adjusting the dose [168].
A recent meta-analysis suggests beneficial effects of glita-
zones, with improvement of dyslipidemia in DM, internal
carotid intima layer thickness reduction, improved fibri-
nolysis, and a direct action of the PPR gamma system at
glomerular, tubular and vascular levels [169]. In theory,
all these actions (hemodynamic, anti-inflammatory, anti-
proliferative and metabolic) would be beneficial actions
in nephropathy [169].
In relation to fractures, a recent meta-analysis showed that
in the female population there has been up to two-fold
increase in the incidence of fractures including both hip
and vertebral fractures [170]. Since a uremic patient has
already an increased osteometabolic risk, a drug that
would increase the incidence of fractures should be ques-
tioned in these patients.
Two representatives of the DPP-4 inhibitors are available,
vildagliptin and sitagliptin. These drugs inhibit the dipep-
tidyl peptidase-4 enzyme which, in turn, prevents degra-
dation of the GLP-1 which remains active longer. Thus
they lead to the reduction of fasting and post-prandial gly-
cemia, without a risk of hypoglycemia. The gliptins sup-
press the high release of glucagon and are neutral as
regards weight. The side effects include airway infection
and transaminases elevation. The standard dose is 100
mg, orally, in a single daily dose. Sitagliptin secretion
occurs mostly in urine and an adjustment in the dose is
recommended according to the stage of renal disease: 50
mg for stage 3 and 25 mg for stages 4 and 5 [171,172]. Vil-
dagliptin also is predominantly excreted in the urine. It is
unnecessary to adjust the dose in patients with mild or
moderate renal failure (50 mg orally, bid). The use of vil-
dagliptin is not recommended, according to the directions
that accompany medications, in patients with severe renal
failure, patients who are already on dialysis or some other
renal substitution therapy.
Exenatide is a GLP-1 analog. Subcutaneous applications
(beginning at 5 μg bid for 30 days and then 10 μg bid)
should be performed up to one hour before meals twice a
day. It is a drug that reduces weight, which may be an
advantage in managing the diabetic patient. The major
side effects are nausea and vomiting, what occasionally an
individual cannot tolerate using it. It is metabolized and
excreted by the kidneys. It presents a low risk of hypogly-
cemia and can be used in stage 3, and it is not recom-
mended in stages 4 and 5 due to the increased risk of side
effects [173].
However, when the renal function is highly compro-
mised, metformin, exenatide and gliptins are contraindi-
cated, and insulin secretagogues are usually not very
effective, since these patients have low endogenous pro-
duction of insulin. Therefore, most patients should be
treated with insulin [153]. We should remember that the
half life of insulin is changed as soon as the individual
begins to have a major renal function impairment. Phar-
macokinetics is modified, and the insulin will have a
slightly longer profile. This may make it difficult to man-
age the day to day situation, in peculiar situations on dif-
ferent days, i.e., the individual who is undergoing a
dialysis session may feel bad and change his diet on that
day. We should be able to rationalize more with the flexi-
bility of doses here, which is often rather difficult for the
patient and the physician.
These individuals certainly will have a greater propensity
to hypoglycemia, so we have to be more careful and
remember that hypoglycemia may be one of the compli-
cations implicated in the increased cardiovascular mortal-
ity of these patients. We should also keep in mind that
therapeutic goals should be individualized.
Dietary intervention
There are several modalities for a dietary intervention in
DN, whether changing protein content or through the
manipulation of lipid content. However, few have their
efficacy shown based on long term randomized clinical
trials.
In patients with type 1 DM, in different stages of renal dis-
ease, protein restriction in the diet has shown that it can
reduce the decline of renal function and albuminuria.
According to a meta-analysis of studies performed with
type 1 DM patients and clinical nephropathy, dietary pro-
tein restriction retards DN progression [174]. However,
several of these studies were randomized with a crossover
design, and the maximum time of follow up was 36Diabetology & Metabolic Syndrome 2009, 1:10 http://www.dmsjournal.com/content/1/1/10
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months. Besides, in these studies there was no evidence of
benefit on hard outcomes such as mortality or risk of end
stage chronic renal failure. A randomized controlled clin-
ical trial with patients with type 1 DM and DN followed
for four years, showed that a diet with a moderate protein
restriction (0.9 g/kg/day) was associated with a 76%
reduction of the risk of end stage chronic renal failure or
death [175].
In patients with type 2 DM this benefit has not been well
established. There are few studies with type 2 DM patients
addressing this issue, showing no benefit on renal func-
tion, probably due to lack of compliance with the diet and
short follow-up [176]. A recent meta-analysis performed
with eight studies including patients with type 1 and 2
DM showed a benefit of protein restriction on proteinuria
reduction, but not on GFR reduction [177]. The American
Diabetes Association recommends moderate protein
restriction (0.8-1.0 g/kg/day) for patients in the initial
stages of DN, and a reduction to 0.8 g/kg/day for patients
in a more advanced stage of this complication [27].
Interventions in the dietary lipid content has also been
suggested, especially by manipulating the type of meat in
the diet. Substituting red meat by chicken meat in the diet
over the short term proved be able to reduce UAE, and
also the serum levels of total cholesterol, LDL and apoli-
poprotein B in patients with type 2 DM and micro and
macroalbuminuria [89,178]. Recently it was also
observed that the beneficial effect of this dietary interven-
tion on renal function was similar to the use of enalapril
for a 12-month period in patients with type 2 DM [179].
This effect is probably related to the lower saturated fat
content and greater proportion of polyunsaturated fatty
acids, observed in chicken meat compared to red meat.
Long term studies are needed to confirm this favorable
effect.
Dyslipidemia
The desired target of LDL is <100 mg/dl for patients with
DM in general, and <70 mg/dl when cardiovascular dis-
ease is present. No data based on a large clinical trial is
available showing that the treatment of dyslipidemia is
able to prevent the development or progression of DN. In
the  Heart Protection Study (HPS), sinvastatin, 40 mg,
reduced vascular event rates and GFR decline in patients
with DM by 25%, independent of baseline cholesterol lev-
els. Furthermore the results of the Collaborative Atorvas-
tatin Diabetes Study (CARDS) demonstrated a marked
reduction in cardiovascular events in DM patients, and at
least one additional risk factor for coronary disease, sug-
gesting that all DM patients should use statins. A recent
publication of CARDS showed a modest beneficial effect
of atorvastatin on eGFR, particularly in those with albu-
minuria [180]. However, atorvastatin did not influence
albuminuria incidence [180].
Multifactorial intervention
As stated before, probably the best approach to a subject
with DN is a multifactorial intervention. However, only
one study, with a small number of patients (n = 160)
addressed this aspect [181]. In this study the targets were:
BP levels <130/80 mm Hg, fasting serum cholesterol <175
mg/dl, fasting serum triglycerides <150 mg/dl, and HbA1c
<6.5%. The intervention consisted of a stepwise imple-
mentation of lifestyle changes and pharmacological ther-
apy including low-fat diet, three to five times a week light-
to-moderate exercise program, smoking-cessation course,
and prescription of ACE inhibitors or ARB and aspirin.
The multiple intervention group had a 61% reduction in
the risk of macroalbuminuria, and a 58% and 63% reduc-
tion in the risk of retinopathy and autonomic neuropathy,
respectively. Most importantly, a 55% reduction in the
risk for the development of a composite end-point con-
sisting of death from cardiovascular causes, non-fatal
myocardial infarction, revascularization procedures, non-
fatal stroke and amputation was also associated with the
multifactorial intervention. It is important to point out
that even among highly motivated subjects only a small
number reached the proposed goals. Less than 20% in the
intensive arm reached the HbA1c goal and less than 50%
the systolic BP goal [181].
Conclusion
Diabetic nephropathy is a chronic complication of DM
with a growing incidence. Therefore it is essential to have
a better understanding of it, especially in relation to pre-
vention and aggressive management to avoid progression
to ESRD. Besides, its direct association with cardiovascular
complications makes it imperative to perform intensive,
early management of the risk factors. The study of DN has
evolved a lot as regards its pathophysiology, stages of
renal involvement and, especially, the therapeutic instru-
ments available. Early detection of DN, the multifactorial
approach targeting the main risk factors (hyperglycemia,
hypertension, dyslipidemia and smoking), and the use of
renoprotective agents such as the drugs that act on the
renin-angiotensin-aldosterone system, may delay progres-
sion of kidney disease in DM, besides reducing cardiovas-
cular mortality.
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